{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:36:24Z","timestamp":1780922184297,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB0830300"],"award-info":[{"award-number":["XDB0830300"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["SIMM0120231004"],"award-info":[{"award-number":["SIMM0120231004"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U2267221"],"award-info":[{"award-number":["U2267221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.nano.2025.102829","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T12:03:56Z","timestamp":1747915436000},"page":"102829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer"],"prefix":"10.1016","volume":"67","author":[{"given":"Xiangning","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renli","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanpeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiguo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2025.102829_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nano.2025.102829_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1533532","article-title":"Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology","volume":"15","author":"Jiang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2025.102829_bb0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.semnuclmed.2023.06.004","article-title":"Future imaging of prostate cancer: do we need more than PSMA PET\/CT?","volume":"54","author":"Vetrone","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"9","key":"10.1016\/j.nano.2025.102829_bb0020","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nano.2025.102829_bb0025","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2025.102829_bb0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ird3.47","article-title":"Harnessing the power of molecular imaging for drug discovery and development","volume":"1","author":"Luo","year":"2023","journal-title":"iRadiology"},{"key":"10.1016\/j.nano.2025.102829_bb0035","first-page":"14","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer","author":"Hennrich","year":"2021","journal-title":"Journal"},{"key":"10.1016\/j.nano.2025.102829_bb0040","first-page":"1292","article-title":"[177Lu]Lu-PSMA-617 (pluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Journal"},{"issue":"1","key":"10.1016\/j.nano.2025.102829_bb0045","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-019-0517-6","article-title":"Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples","volume":"9","author":"Schollhammer","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nano.2025.102829_bb0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pros.20957","article-title":"Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer","volume":"69","author":"Ananias","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.nano.2025.102829_bb0055","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/pros.21434","article-title":"Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates","volume":"72","author":"Beer","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.nano.2025.102829_bb0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1387\/ijdb.041954ho","article-title":"Development and function of bombesin-like peptides and their receptors","volume":"49","author":"Ohki-Hamazaki","year":"2005","journal-title":"Int J Dev Biol"},{"key":"10.1016\/j.nano.2025.102829_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.107.07108","article-title":"International Union of Pharmacology. LXVIII. Mammalian Bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states","volume":"60","author":"Jensen","year":"2008","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.nano.2025.102829_bb0070","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00259-006-0347-4","article-title":"DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours","volume":"34","author":"Zhang","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2025.102829_bb0075","first-page":"1144","article-title":"177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer","volume":"47","author":"Lantry","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nano.2025.102829_bb0080","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.2967\/jnumed.109.064444","article-title":"177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression","volume":"50","author":"Maddalena","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nano.2025.102829_bb0085","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ymeth.2009.04.002","article-title":"Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues","volume":"48","author":"Schroeder","year":"2009","journal-title":"Methods"},{"key":"10.1016\/j.nano.2025.102829_bb0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14737159.2022.2145187","article-title":"Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives","volume":"22","author":"Gorica","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.nano.2025.102829_bb0095","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","article-title":"Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours","volume":"38","author":"Mansi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2025.102829_bb0100","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1021\/bc300659k","article-title":"Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging","volume":"24","author":"Varasteh","year":"2013","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nano.2025.102829_bb0105","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00259-015-3232-1","article-title":"Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET\/CT","volume":"43","author":"Maina","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2025.102829_bb0110","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.3390\/molecules190710455","article-title":"The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin","volume":"19","author":"Varasteh","year":"2014","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.nano.2025.102829_bb0115","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.nucmedbio.2014.12.009","article-title":"The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26","volume":"42","author":"Varasteh","year":"2015","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nano.2025.102829_bb0120","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s00259-022-05750-8","article-title":"Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers","volume":"49","author":"Xu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nano.2025.102829_bb0125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/ic960665v","article-title":"Design, synthesis, and X-ray structural characterization of new dinucleating macrocyclic ligands and a novel phenolate-bridged dilanthanum(III) complex","volume":"36","author":"Wang","year":"1997","journal-title":"Inorg Chem"},{"key":"10.1016\/j.nano.2025.102829_bb0130","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/17460441.2012.714363","article-title":"The influence of lipophilicity in drug discovery and design","volume":"7","author":"Arnott","year":"2012","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.nano.2025.102829_bb0135","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2967\/jnumed.117.198192","article-title":"Will GRPR compete with PSMA as a target in prostate cancer?","volume":"58","author":"Iagaru","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963425000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963425000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:53:43Z","timestamp":1778313223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963425000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"alternative-id":["S1549963425000292"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2025.102829","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2025.102829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102829"}}